ARCT Arcturus Therapeutics: Company Short-Term Debts

Public company logo of Arcturus Therapeutics (ARCT)

The market dynamics of Arcturus Therapeutics (ARCT) securities highlight cash flow instability due to grant dependency, with the indicator standing at 0.00. The business relies on the full outsourcing of mRNA drug production and testing, focusing exclusively on research. A strong patent portfolio and unique developments protect Arcturus Therapeutics (ARCT) from price wars, shifting the competition toward scientific efficacy.

ARCT (Arcturus Therapeutics Holdings Inc.) Company Short-Term Debts history from 07/04/2022 to 10/31/2026

Metric breakdowns and analytics for Arcturus Corp (ARCT)

- stock price and consensus target price:
Stock Price Arcturus Therapeutics Holdings Inc.|ARCT - Consensus Target
- company stock capitalization data:
Market Capitalization Arcturus Therapeutics Holdings Inc.|ARCT - Company Buyout Price
- business book valuation details:
Book Value per Share Arcturus Therapeutics|ARCT - Book Capitalization|Market Value to Book Value Ratio arcturusrx.com|ARCT - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Arcturus Therapeutics|ARCT - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio Arcturus Therapeutics|ARCT - Company Aggregate Indebtedness|Debts to Book Capitalization Arcturus Therapeutics Holdings Inc.|ARCT - Long-Term Debt|Company Short-Term Debts Arcturus Therapeutics|Quick Liquidity Indicator arcturusrx.com
- net income and valuation multiples indicators:
ARCT - Final Profit
Summary company analysis:Arcturus Therapeutics Holdings Inc. (ARCT)
Manufactured products of arcturusrx.com

Assessing stock reliability requires an analysis of the issuer's liquidity and debt load. This indicator captures the total liabilities with a maturity of up to one year. For Arcturus Therapeutics (ARCT) and its LUNAR mRNA platform, controlling these payments is critical when financing R&D. A reduction in debt confirms financial recovery, whereas an excessive minimum may signal a credit limit. The dynamics of short-term loan capital volume determine the stability of the business model.

Main competitors

Vertex - Company Short-Term Debts|Alnylam Pharmaceuticals, Inc. (ALNY) - Company Current Liabilities|INSM: Company Short-Term Debts|UTHR - Short-Term Debt Volume|BMRN (BioMarin Pharmaceutical) - Company Short-Term Debts|Company Short-Term Debts bridgebio.com|Company Short-Term Debt BGM Group Ltd (BGM)|Company Short-Term Debt COGT (Cogent Biosciences Inc)|Company Short-Term Debts XERS (Xeris Biopharma Inc)|Short-Term Debt Volume Keros Corp (KROS)|ETON: Company Current Liabilities|Current Liabilities KMDA|FULC: Company Short-Term Debts|Short-Term Debt Abeona Therapeutics Inc. (ABEO)|MREO (Mereo BioPharma Group) - Company Short-Term Debts|Company Short-Term Indebtedness PLX (Protalix BioTherapeutics, Inc)|Company Current Liabilities PLRX (Pliant Therapeutics)|APLT (Applied Therapeutics Inc.) - Company Short-Term Loans and Borrowings|Company Short-Term Debt Rein Therapeutics RNTX|GELS (Gelteq Ltd) - Current Liabilities|Aytu Therapeutics - Company Short-Term Debts|Company Short-Term Loans and Borrowings CMMB (Chemomab Therapeutics)|SRXH: Company Short-Term Debts|Polyrizon (PLRZ) - Company Short-Term Debts|Company Short-Term Debt Aeterna Zentaris Inc|CYTH: Company Short-Term Loans and Borrowings|Company Short-Term Debt Inozyme Pharma, Inc. (INZY)|Company Current Liabilities Reneo Pharmaceuticals, Inc RPHM|Company Short-Term Debts CSCI (COSCIENS Biopharma Inc.)